Status:
RECRUITING
Risk Factors Affecting MSC Efficacy in ACLF Patients
Lead Sponsor:
Sun Yat-sen University
Conditions:
Acute-On-Chronic Liver Failure
Eligibility:
All Genders
18+ years
Brief Summary
Mesenchymal stromal cells (MSCs) are potential therapy for many diseases, with the ability of tissue regeneration, repair and immunomodulation. Acute-on-chronic liver failure (ACLF) is a severe diseas...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute-on-chronic liver failure; Positive serum HBV surface antigen for more than 6 months; Received MSCs infusion more than one time.
Exclusion
- Systemic or local malignancy; Hepatitis C virus infection; HIV infection or other immunodeficiency disease; Marked organ dysfunction (e.g., renal dysfunction); Pregnancy or lactation; Hyperthyroidism or other primary thyroid diseases; Incomplete data or lost to follow-up; Hospital stay \< 1 day.
Key Trial Info
Start Date :
October 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
446 Patients enrolled
Trial Details
Trial ID
NCT07198854
Start Date
October 20 2025
End Date
June 30 2026
Last Update
November 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630